Read more
This volume thoroughly covers HIV-1 antiretrovirals currently in clinical use, together with their advantages and limitations. HIV-1 inhibitor resistance is discussed in detail, and critical assessments as to what will be required of future antiretrovirals in order to halt viral replication, reduce viral resistance, and alter the state of viral latency are presented. Experts at the forefront of HIV-1 research provide overviews of approaches from the fields of virology, chemical biology and structural biology for obtaining small molecule inhibitors that target viral regulatory and structural components at multiple points in the viral lifecycle. The individual chapters will appeal to scientists and clinicians alike.
List of contents
HIV Therapy Looking Towards the Future.- Computational challenges of structure-based approaches applied to HIV.- Nucleocapsid Protein: A Desirable Target For Future Therapies Against HIV-1.- HIV-1 integrase multimerization as a therapeutic target.- Targeting HIV transcription: The quest for a functional cure.- Targeting the HIV RNA Genome: High-Hanging Fruit Only Needs a Longer Ladder.- HIV-1 Gag: An Emerging Target for Antiretroviral Therapy.- The Triple Threat of HIV-1 Protease Inhibitors.- Illustrations of the HIV Life Cycle.
About the author
Dr. David S. Goodsell ist Assistenzprofessor in der Abteilung für Molekularbiologie am Scripps Research Institute in La Jolla, Kalifornien. Seine Abbildungen sind berühmt und erscheinen in vielen Publikationen, um zu zeigen, wie dicht gepackt und übervoll Zellen sind. Goodsell ist auch als Fachmann und bei Illustrationen vieler Wissenschafts-Museen gefragt, erst kürzlich wurde er bei einer neuen Nanotechnologie-Initiative, die teilweise vom Exploratorium in San Francisco ausging, um Rat gefragt.
Report
"The book does a fantastic job of addressing new approaches to inhibit HIV-1. ... this is a useful book that can be used by researchers, HIV clinicians, and medicinal chemists interested in investigating new molecules for the treatment of HIV-1. It addresses novel areas that have no chemical entities that are FDA approved. There are no books that compete with this one." (Christopher J. Destache, Doody's Book Reviews, September, 2015)
"This book includes 8 comprehensive, heavily referenced chapters on antiretroviral drug development. ... a comprehensive, readable review of a subject that brings together 2 or more decades of molecular virology research and drug development. ... the chapters in this book are likely to be, for the next several years, highly useful and popular starting points for learning about new areas in HIV drug development." (Robert W. Shafer, Clinical Infectious Diseases, September, 2015)
